ANI Pharmaceuticals (ANIP) stock is surging 6.25% in pre-market trading on Friday following the company's announcement of record-breaking first-quarter results for 2025 and an increase in its full-year guidance. The pharmaceutical company's performance significantly exceeded analyst expectations, demonstrating robust growth and improved financial outlook.

For the first quarter of 2025, ANI Pharmaceuticals reported adjusted earnings per share (EPS) of $1.70, handily beating the FactSet consensus estimate of $1.38. The company's revenue also outperformed, reaching $197.12 million compared to the analyst forecast of $180.68 million. This strong financial performance represents substantial growth from the same period last year when the company reported earnings of $1.21 per share.

In light of these impressive results, ANI Pharmaceuticals has raised its guidance for the full year 2025. The company now expects adjusted EPS in the range of $6.27 to $6.62, up from its previous forecast of $6.12 to $6.49. Additionally, ANI has increased its revenue outlook to between $768 million and $793 million, compared to the earlier projection of $756 million to $776 million. This upward revision in guidance suggests management's confidence in the company's continued growth trajectory and operational efficiency. The market's strongly positive reaction to this news underscores investor optimism about ANI Pharmaceuticals' future prospects.